Back to all webinars
Global Expert Exchange: IO therapy for advanced NSCLC with no oncogenic driver mutations
Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe.
Speakers
Treatment guidelines for first-line IO in advanced NSCLC
No entries
IO-monotherapy for advanced NSCLC with a PD-L1 TPS of ≥50%
No entries
First line chemo-IO in advanced NSCLC
No entries
Chemo-IO versus IO-IO in advanced NSCLC
No entries
Second line and later treatments for advanced NSCLC
No entries
IO in patients with a poor patient performance status
No entries
IO in patients with comorbidities
No entries
IO in patients with CNS metastases
No entries
Discussion: Global variations in clinical practice
No entries
Clinical case sharing (Europe)
No entries
Clinical case sharing (China)
No entries
Discussion: Individualizing treatment decisions
No entries
Panel discussion
No entries